SCHEMBL515156

SCHEMBL515156

CCCCCCCCCCCCCCCCCCOC(=O)CO.[NaH]

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.69
RAD52 P43351 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
DGKA P23743 1/20 0.57
FAAH O00519 2/20 0.56
HTR2C P28335 1/20 0.55
EPHX1 P07099 1/20 0.53
TSHR P16473 3/20 0.52
PRSS1 P07477 1/20 0.49
PRSS2 P07478 1/20 0.49
PRSS3 P35030 1/20 0.49
HCAR2 Q8TDS4 1/20 0.48
DNM1 Q05193 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
ACHE P22303 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27766562 1.00 NAAA (0.69) NAAARAD52NPSR1DGKAFAAH
SCHEMBL6561692 1.00 NAAA (0.69) NAAARAD52NPSR1DGKAFAAH
SCHEMBL20067027 0.98 NAAA (0.72) NAAARAD52NPSR1DGKAFAAH
SCHEMBL11125285 0.98 NAAA (0.65) NAAARAD52NPSR1DGKAFAAH
SCHEMBL5448501 0.98 NAAA (0.72) NAAARAD52NPSR1DGKAFAAH
SCHEMBL1548190 0.98 NAAA (0.72) NAAARAD52NPSR1DGKAFAAH
SCHEMBL4332027 0.98 NAAA (0.72) NAAARAD52NPSR1DGKAFAAH
SCHEMBL5696640 0.98 NAAA (0.72) NAAARAD52NPSR1DGKAFAAH
SCHEMBL5440890 0.98 NAAA (0.72) NAAARAD52NPSR1DGKAFAAH
SCHEMBL95547 0.98 NAAA (0.72) NAAARAD52NPSR1DGKAFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917973-A1 Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof Teva Pharmaceutical Industries Ltd (IL) 2008-05-07 EP claimed
EP-1864677-B1 Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof TEVA PHARMA (IL) 2008-01-02 EP claimed
EP-1864677-A1 Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof Teva Pharmaceutical Industries Ltd (IL) 2007-12-12 EP claimed
CN-118829416-A Composition (III) 西姆莱斯股份公司 2024-10-22 CN disclosed
EP-2395838-B1 STABLE PHARMACEUTICAL COMPOSITION FOR ATHEROSCLEROSIS CADILA PHARMACEUTICALS LTD (IN) 2018-07-25 EP disclosed
US-9789187-B2 Stable pharmaceutical composition for atherosclerosis CADILA PHARMACEUTICALS LIMITED (IN) 2017-10-17 US disclosed
US-20120027849-A1 STABLE PHARMACEUTICAL COMPOSITION FOR ATHEROSCLEROSIS CADILA PHARMACEUTICALS LIMITED (IN) 2012-02-02 US disclosed
EP-1917973-A1 Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof Teva Pharmaceutical Industries Ltd (IL) 2008-05-07 EP disclosed
EP-1864677-B1 Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof TEVA PHARMA (IL) 2008-01-02 EP disclosed
WO-2007142628-A1 STABLE FORMULATION COMPRISING MOISTURE SENSITIVE DRUG/S AND MANUFACTURING PROCEDURE THEREOF TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2007-12-13 WO disclosed
EP-1864677-A1 Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof Teva Pharmaceutical Industries Ltd (IL) 2007-12-12 EP disclosed
US-20070281000-A1 Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2007-12-06 US disclosed